Navigation Links
Advanced Life Sciences to Host 2010 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
Date:3/17/2011

CHICAGO, March 17, 2011 /PRNewswire/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), announced today that it will host a conference call and webcast discussing the Company's 2010 fourth quarter and full-year financial results on Thursday, March 24, 2011 at 9:00 AM (EDT). Michael T. Flavin, Ph.D., Chairman & Chief Executive Officer, as well as other members of the management team, will also present an update on the Company. A press release reporting the 2010 fourth quarter and full-year results will be issued before the U.S. stock markets open on Thursday, March 24, 2011.

(Logo:  http://photos.prnewswire.com/prnh/20080218/ALSLOGO)

The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 888-713-4211 (domestic) or 617-213-4864 (international). The passcode for the conference call is 86880056. Investors are advised to dial into the call at least ten minutes prior to the call to register. Participants may pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=PAVMV3UD3.

Pre-registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection.

A replay of the conference call will be available until March 31, 2011. Callers may access the telephone replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 75965641.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Teysuno™ (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer
2. Greg Miller of Advanced Health Media Named New Jersey Technology Council CIO of the Year
3. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
4. Lab-on-a-Chip - ICAP Ocean Tomo Announces Auction of Patents for Advanced Techniques in Bio-Organic Analysis and Synthesis
5. Salk Institute Celebrates Grand Opening of the Waitt Advanced Biophotonics Center
6. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
7. Advanced Health Media Company Announces Renee DeFranco as Senior Vice President - Human Resources
8. New materials may bring advanced optical technologies, cloaking
9. Advanced Pain Remedies, a Subsidiary of Cato BioVentures, Announces a Three Million Dollar Award from the National Cancer Institute for SP-SAP
10. Advanced BioHealing to Present at 29th Annual J.P. Morgan Healthcare Conference
11. Advanced Life Sciences to Present at the Biotech Showcase™ 2011 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... A new study ... setting of previously treated, advanced pancreatic cancer, liquid biopsies are not yet an ... and timing of blood sampling may improve the value of a blood-based test.” ...
(Date:12/7/2016)... 7, 2016  Nordion, a standalone business of ... welcome today,s award by the United States Department ... of the Phase II cooperative agreement funding to ... the University of Missouri Research Reactor Center (MURR ... the establishment of a new, reliable supply of ...
(Date:12/7/2016)... Dec. 7, 2016  Muse bio, a privately-held company ... announced that Dr. Kevin Ness has been ... of Directors. Kevin succeeds Muse bio,s ... company,s Chief Science Officer as well as remains Slade ... the BioDesign Center at the RAS Energy Institute at ...
(Date:12/7/2016)... ... December 07, 2016 , ... JULABO USA is ... cart. The new website has been designed to provide the best user-friendly experience ... to access detailed product information, read educational industry content as well as share ...
Breaking Biology Technology:
(Date:12/2/2016)... December 1, 2016 The ... Voice), Future Technology (Iris Recognition System), Vehicle Type ... Global Forecast to 2021", published by MarketsandMarkets, the ... in 2016, and is projected to grow to ... of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/29/2016)... BioDirection, a privately held medical device company ... detection of concussion and other traumatic brain injury (TBI), ... meeting with the U.S. Food and Drug Administration (FDA) ... During the meeting company representatives reviewed plans for clinical ... commencement of a planned pilot trial. ...
(Date:11/24/2016)... 23, 2016 Cercacor today introduced Ember TM ... trainers non-invasively measure hemoglobin, Oxygen Content, Oxygen ... Respiration Rate in approximately 30 seconds. Smaller than a ... immediate access to key data about their bodies to ... regimen. Hemoglobin carries oxygen to muscles. ...
Breaking Biology News(10 mins):